OVID
Ovid Therapeutics Inc
2.30$
-1.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | |
| 369.2% | 282.7% | 91.9% | 87.6% | 97.7% | – | 218.5% | 1.6% | 12.9% | 6.1% | – | 2.2% | 7.1% | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 97.8% | |
| 4,892.7% | 7,494.4% | 7,025.0% | 7,445.0% | 4,540.5% | 7,793.4% | 5,122.3% | 103.1% | 4,447.0% | 917.7% | – | 1,358.4% | 2,122.4% | |
| 6,243.1% | 4,357.7% | 4,843.2% | 4,795.3% | 3,204.6% | 8,914.5% | 4,631.5% | 77.8% | 5,140.2% | 894.4% | – | 842.3% | 1,645.4% | |
| 11,135.8% | 12,908.5% | 11,868.2% | 12,240.2% | 7,745.1% | 14,207.9% | 9,753.8% | 180.9% | 9,587.1% | 1,812.1% | – | 2,241.6% | 3,786.7% | |
| -11,035.8% | -12,808.5% | -11,768.2% | -12,140.2% | -7,645.1% | -14,107.9% | -9,653.8% | -80.9% | -9,487.1% | -1,712.1% | – | -2,141.6% | -3,686.7% | |
| – | 1,081,757.7% | – | – | – | – | – | – | – | – | – | – | – | |
| -10,323.9% | -10,790.1% | -7,901.4% | 5,042.0% | -8,096.0% | -12,175.0% | -7,873.1% | -74.7% | -9,210.6% | 1,345.8% | – | -2,047.6% | -2,178.9% | |
| 0.2% | 0.0% | 62.7% | – | – | – | – | – | – | – | – | – | – | |
| -10,323.9% | -10,790.1% | -7,901.4% | 5,042.0% | -8,096.0% | -12,175.0% | -7,873.1% | -74.7% | -9,210.6% | 1,345.8% | – | -2,047.6% | -2,178.9% | |
| -10,189.9% | -11,512.7% | -7,809.5% | 5,129.6% | -7,998.3% | -14,160.5% | -7,764.6% | -73.1% | -9,198.5% | 1,348.2% | – | -2,098.5% | -2,252.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.